Trajectory of Viral RNA Load Among Persons With Incident SARS-CoV-2 G614 Infection (Wuhan Strain) in Association With COVID-19 Symptom Onset and Severity.
Journal
JAMA network open
ISSN: 2574-3805
Titre abrégé: JAMA Netw Open
Pays: United States
ID NLM: 101729235
Informations de publication
Date de publication:
04 01 2022
04 01 2022
Historique:
entrez:
10
1
2022
pubmed:
11
1
2022
medline:
20
1
2022
Statut:
epublish
Résumé
The SARS-CoV-2 viral trajectory has not been well characterized in incident infections. These data are needed to inform natural history, prevention practices, and therapeutic development. To characterize early SARS-CoV-2 viral RNA load (hereafter referred to as viral load) in individuals with incident infections in association with COVID-19 symptom onset and severity. This prospective cohort study was a secondary data analysis of a remotely conducted study that enrolled 829 asymptomatic community-based participants recently exposed (<96 hours) to persons with SARS-CoV-2 from 41 US states from March 31 to August 21, 2020. Two cohorts were studied: (1) participants who were SARS-CoV-2 negative at baseline and tested positive during study follow-up, and (2) participants who had 2 or more positive swabs during follow-up, regardless of the initial (baseline) swab result. Participants collected daily midturbinate swab samples for SARS-CoV-2 RNA detection and maintained symptom diaries for 14 days. Laboratory-confirmed SARS-CoV-2 infection. The observed SARS-CoV-2 viral load among incident infections was summarized, and piecewise linear mixed-effects models were used to estimate the characteristics of viral trajectories in association with COVID-19 symptom onset and severity. A total of 97 participants (55 women [57%]; median age, 37 years [IQR, 27-52 years]) developed incident infections during follow-up. Forty-two participants (43%) had viral shedding for 1 day (median peak viral load cycle threshold [Ct] value, 38.5 [95% CI, 38.3-39.0]), 18 (19%) for 2 to 6 days (median Ct value, 36.7 [95% CI, 30.2-38.1]), and 31 (32%) for 7 days or more (median Ct value, 18.3 [95% CI, 17.4-22.0]). The cycle threshold value has an inverse association with viral load. Six participants (6%) had 1 to 6 days of viral shedding with censored duration. The peak mean (SD) viral load was observed on day 3 of shedding (Ct value, 33.8 [95% CI, 31.9-35.6]). Based on the statistical models fitted to 129 participants (60 men [47%]; median age, 38 years [IQR, 25-54 years]) with 2 or more SARS-CoV-2-positive swab samples, persons reporting moderate or severe symptoms tended to have a higher peak mean viral load than those who were asymptomatic (Ct value, 23.3 [95% CI, 22.6-24.0] vs 30.7 [95% CI, 29.8-31.4]). Mild symptoms generally started within 1 day of peak viral load, and moderate or severe symptoms 2 days after peak viral load. All 535 sequenced samples detected the G614 variant (Wuhan strain). This cohort study suggests that having incident SARS-CoV-2 G614 infection was associated with a rapid viral load peak followed by slower decay. COVID-19 symptom onset generally coincided with peak viral load, which correlated positively with symptom severity. This longitudinal evaluation of the SARS-CoV-2 G614 with frequent molecular testing serves as a reference for comparing emergent viral lineages to inform clinical trial designs and public health strategies to contain the spread of the virus.
Identifiants
pubmed: 35006245
pii: 2787768
doi: 10.1001/jamanetworkopen.2021.42796
pmc: PMC8749477
doi:
Substances chimiques
RNA, Viral
0
Types de publication
Journal Article
Randomized Controlled Trial
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e2142796Subventions
Organisme : NIAID NIH HHS
ID : UM1 AI148684
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA213130
Pays : United States
Références
JAMA Netw Open. 2020 Jul 1;3(7):e2016382
pubmed: 32697321
Nature. 2021 Apr;592(7854):438-443
pubmed: 33690265
Infect Control Hosp Epidemiol. 2021 Jun;42(6):659-668
pubmed: 33077007
Antimicrob Agents Chemother. 2013 Dec;57(12):5820-9
pubmed: 24018260
JAMA Pediatr. 2021 Oct 1;175(10):e212025
pubmed: 34115094
J Med Virol. 2020 Nov;92(11):2286-2287
pubmed: 32347980
J Infect Dis. 2021 May 28;223(10):1666-1670
pubmed: 33580259
J Infect Dis. 2020 Jul 25;:
pubmed: 32710762
J Clin Microbiol. 2020 Jul 23;58(8):
pubmed: 32350048
N Engl J Med. 2020 Jul 9;383(2):185-187
pubmed: 32356944
Lancet Infect Dis. 2021 Jan;21(1):52-58
pubmed: 33058797
Nature. 2020 Aug;584(7821):457-462
pubmed: 32668444
JAMA Pediatr. 2021 Jan 1;175(1):73-80
pubmed: 32857112
J Infect Dis. 2021 Feb 13;223(3):409-415
pubmed: 32692346
Science. 2020 Dec 11;370(6522):1339-1343
pubmed: 33159009
J Infect Dis. 2011 Aug 15;204(4):554-61
pubmed: 21791657
Int J Infect Dis. 2020 Jul;96:288-290
pubmed: 32437933
Lancet Infect Dis. 2020 Jun;20(6):656-657
pubmed: 32199493
Lancet Infect Dis. 2021 May;21(5):629-636
pubmed: 33545090
Cell Host Microbe. 2020 Jun 10;27(6):863-869
pubmed: 32464098
Nature. 2020 May;581(7809):465-469
pubmed: 32235945
JAMA. 2021 Feb 16;325(7):632-644
pubmed: 33475701
PLoS Biol. 2021 Jul 12;19(7):e3001333
pubmed: 34252080
J Infect Dis. 2021 Jan 4;223(1):15-18
pubmed: 33020822
Sci Adv. 2020 Nov 20;6(47):
pubmed: 33097472
Science. 2021 Apr 9;372(6538):
pubmed: 33658326
Lancet Microbe. 2021 Jan;2(1):e13-e22
pubmed: 33521734
Sci China Life Sci. 2020 May;63(5):706-711
pubmed: 32146694
N Engl J Med. 2021 Jan 21;384(3):238-251
pubmed: 33332778
N Engl J Med. 2020 Mar 19;382(12):1177-1179
pubmed: 32074444
J Clin Microbiol. 2020 Dec 17;59(1):
pubmed: 33046529
N Engl J Med. 2020 May 28;382(22):2081-2090
pubmed: 32329971
J Infect. 2020 Sep;81(3):357-371
pubmed: 32615199
JAMA Intern Med. 2020 Nov 1;180(11):1447-1452
pubmed: 32780793
Ann Intern Med. 2021 Mar;174(3):344-352
pubmed: 33284679
Nat Med. 2020 May;26(5):672-675
pubmed: 32296168
Nat Rev Immunol. 2020 Aug;20(8):457-458
pubmed: 32636479
J Biomed Inform. 2019 Jul;95:103208
pubmed: 31078660
Lancet Infect Dis. 2021 Sep;21(9):1246-1256
pubmed: 33857406
Emerg Infect Dis. 2021 Feb;27(2):352-359
pubmed: 33275874
Nature. 2021 May;593(7858):266-269
pubmed: 33767447
Clin Infect Dis. 2021 Nov 2;73(9):e2946-e2951
pubmed: 32840608
Clin Microbiol Infect. 2020 Nov;26(11):1556.e1-1556.e6
pubmed: 32653662